Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
6710 results about "Antibiotic drug" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibiotics, also known as antibacterials, are medications that destroy or slow down the growth of bacteria. They include a range of powerful drugs and are used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs.
Application of lipid vehicles and use for drug delivery
InactiveUS7063860B2Reduce and prevent antibody-mediated resistanceIncrease stimulationBiocideAntipyreticAnticarcinogenCapsaicin
The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.
Owner:UNIVERSITY OF PITTSBURGH
Particulate acellular tissue matrix
Owner:LIFECELL
Compositions and methods for treating cystic fibrosis
InactiveUS20100303917A1Increased mucus secretionReduce airflowBiocidePowder deliveryTobramycinCell membrane
Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and / or synergy with tobramycin for treating bacterial infection, and use and / or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions).
Owner:REVALESIO CORP
Apparati, methods, and compositions for universal microbial diagnosis, detection, quantification, and specimen-targeted therapy
InactiveUS20120129794A1Increase productivityAccurate and rapid and sensitive microbial diagnosis and detection and quantificationAntibacterial agentsBiocidePopulationMolecular Targeted Therapies
Microbial ecology of a specimen is evaluated using an approach (Level I) that utilizes nucleic acid amplification with specific gene primers that will identify panels of microorganisms and antibiotic-resistance factors generating a diagnostic report (optionally with quantification of each microorganism or antibiotic-resistance factor) and an approach (Level II) that utilizes universal or semi-universal primers to amplify conserved genes at a general or specific taxonomic level that are tagged specimen specifically using a genetic or chemical marker that is specific to the specimen from which it was derived, then sequencing the amplified products with highly-parallel, high-throughput technology to provide comprehensive sequences of the microbial population in the specimen followed by analysis of this sequence information and specific targeted information from Level I and / or Level II to generate a comprehensive analysis, interpretation, and / or diagnostic report.
Owner:DOWD SCOT E +2
Water soluble nanoparticles and method for their production
InactiveUS20050191359A1Readily bioavailableLow costPowder deliveryBiocidePolymer scienceNanoparticle
Hydrophilic dispersions of stable nano-sized particles are provided comprising: (a) a water-insoluble or water-soluble active compound, wherein said active compound is selected from the group consisting of a macrolide antibiotic, donepezil hydrochloride, an azole compound and a taxane; and (b) an amphiphilic polymer which wraps said active compound in a non-crystalline manner to form a nano-sized molecular entity in which no valent bonds are formed.
Owner:SOLUBEST
Microbial ecological traditional Chinese medicine preparation for livestock and poultry from fermentation production of multiple bacterials and fermentation method thereof
ActiveCN101401921ALow costImmunity exceedsFungiAnthropod material medical ingredientsHouttuyniaLactobacillus acidophilus
The invention relates to micro-ecological Chinese medicine preparation for livestock and poultry by adoption of multi-strain fermentation production and a fermentation method. The compositions of traditional Chinese medicines in a culture medium of the fermentation preparation include: radix astragali, radix codonopsitis, Atractylodes macrocephala, Poria cocos, liquorice, medicated leaven, hawkthorn, angelica, Chinese rhubarb, Scutellaria baicalensis, radix isatidis, cordate houttuynia, sicklesenna seeds, Schisandra chinensis, Gynostemma pentaphylla, phellodendron, dried orange peel, radix bupleuri, curcuma, honeysuckle, Chinese gall, purslane and Quisqualis indica. The fermentation method is as follows: a multi-strain solid state fermentation strain is adopted for fermentation; bacillus subtilis, bacillus natto, bacillus licheniformis, beer yeast, Candida wtilis, Aspergillus niger, lactobacillus plantarum, Lactobacillus acidophilus and bifidobacteria are purified and subjected to anaerobic fermentation under the conditions of a rotating speed of 180 revolutions per minute at a temperature is 32 DEG C for 48 to 72 hours till the pH value reaches 4.0. The micro-ecological Chinese medicine preparation has the advantages that the micro-ecological Chinese medicine preparation uses probiotics to ferment different Chinese medicine compositions, and is micro-ecological Chinese medicine preparation which completely replaces antibiotics and has the advantages of no residual medicine, disease prevention, growth promotion and low cost.
Owner:河南省龙腾高科实业有限公司
Defined serumfree medical solution for ophthalmology
A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements, and a growth factor(s) which maintains and enhances the preservation of eye tissues, including human corneal, retinal and corneal epithelial tissues at low to physiological temperatures (2 DEG C. to 38 DEG C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing agents, an antibiotic(s) and / or antimycotic agent(s), ATP or energy precursors, nutrient cell supplements, coenzymes and enzyme supplements, nucleotide precursors, hormonal supplements, non-essential amino acids, trace minerals, trace elements and a growth factor(s).
Owner:SKELNIK DEBRA L
Disposable sheath for specula
A speculum sheath which covers a speculum and methods for using the sheath are described herein. A variety of different types of specula may be covered with the sheath, including anal, vaginal, ear, and nasal specula. The sheath is made of a compliant or partially compliant material, including latex, vinyl, natural and synthetic rubbers, silicone, nylon, polyethylene, polypropylene, and non-degradable or degradable elastomers. The material may be transparent or opaque. In the preferred embodiment, the material is transparent. The sheath may contain one or two openings. Optionally, the sheath contains an affixing means on the inside of or at least one of the openings on the sheath to prevent slippage when in contact with the speculum. Optionally, the sheath contains an active agent, such as hemostatic agents, anti-infectives, antibiotics, antimitotics anti-inflammatory, or other chemotherapeutic agents. In the preferred embodiment, the sheath is placed on a vaginal speculum and supports loose vaginal tissue when inserted into a patient. In the most preferred embodiment, the material is transparent so that medical provider may view the lumen.
Owner:ENDOLUMINAL THERAPEUTICS
Fluid management flow implants of improved occlusion resistance
ActiveUS20060074388A1Reduce probabilityMaterial is expensiveWound drainsSurgeryDrugCerebrospinal fluid
This invention relates to achieving or improving uniform distribution of fluid flow in medical devices such as when combined with antibiotics impregnated in a catheter and / or with a drug-eluting catheter to further inhibit the catheter from becoming occluded by debris in the CSF or by bacterial biofilm formation or tissue proliferation in the catheter.
Owner:INTEGRA LIFESCI SWITZERLAND SARL
Compound microbial agent for degrading antibiotic and pesticide residues as well as preparation and application thereof
InactiveCN106434430AEliminate pollutionAchieve biodegradableFungiBacteriaEcological environmentBacillus megaterium
The invention relates to a compound microbial agent for degrading antibiotic and pesticide residues as well as preparation and application thereof, and belongs to the field of biotechnology and environmental protection. Multi-thallus compound microbial powder is prepared from the compound microbial agent according to the weight percentage of living microbes to the total amount of compound microbial powder as follows: 10%-15% of bacillus subtilis, 10%-15% of aspergillus niger, 10%-15% of bacillus mucilaginosus, 10%-15% of enterococcus faecalis, 8%-12% of bacillus licheniformis, 8%-12% of bacillus megaterium, 8%-12% of pseudomonas fluorescens, 5%-8% of lactobacillus plantarum, 5%-8% of bacillus polymyxin and 6%-8% of streptococcus thermophiles. The compound microbial agent has the effects of degrading antibiotic and pesticide residues, fermenting and composting organic matter, acting as functional fertilizer and repairing the environment, and can solve the problems of secondary pollution caused by antibiotic residues in culture feces and resource utilization of organic waste and realizes biodegradation of the antibiotic and pesticide residues in soil when applied to the agricultural ecological environment, thereby being of great value and practical significance in restoration of agricultural ecological environment and protection of human health.
Owner:中山市润泽生物科技有限公司
Micro-ecological preparation and application thereof
The invention relates to a micro-ecological preparation and the application thereof, in particular to a micro-ecological preparation containing a variety of probiotics and the application thereof. The micro-ecological preparation contains any three or four of the components including CGMCC No. 2383 bacillus licheniformis powder, bacillus subtilis powder, CGMCC No. 2386 enterococcus faecalis powder, lactobacillus acidophilus powder, and CGMCC No. 2388 saccharomyces cerevisiae. The micro-ecological preparation has content of live bacteria, has the adversity resistance such as gastric acid resistance, bile salt resistance, high-temperature resistance, common antibiotic resistance, and the like and the probiotic functions of producing acid and enzyme and resisting pathogenic bacteria. The variety and the proportion of the probiotics and carrier can be determined according to different kinds of animals and different animal growth phase. The micro-ecological preparation can improve the feed utilization efficiency, increase the yield of meat, eggs and milk, promote the growth of the animal, improve the immunity and the disease resistance of the animal, replace the antibiotic and improve the quality of the animal product.
Owner:BEIJING DABEINONG TECH GRP CO LTD +1
Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents
The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q-(Y1)p-(U)p-(Y2)p-A: wherein Q represents an aminoquinoline, (Y1)p(U)p-(Y2)p'' is an optional spacer and A is an antibiotic residue. The invention enables the antibiotic residue activity to be unexpectedly enhanced.
Owner:PALUMED +1
Enterococcus faecium ANSE228 and application thereof
ActiveCN102031235AIncrease production capacityReduce the death rateAntibacterial agentsBacteriaEscherichia coliStaphylococcus cohnii
The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and / or Escherichia coli and / or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and / or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.
Owner:科润生科技发展有限公司
Tool For Extracting Vitreous Samples From An Eye
InactiveUS20070078359A1Prevent undesirable increase in intraocular pressureAvoid cross contaminationEye surgerySurgeryEngineeringAntibiotic Y
A unitary mechanical injector-vitrector hand tool for use in extracting vitreous material from an eye and injecting another fluid into the eye includes a housing body having a proximal end, a distal end and a variable volume cavity in the housing body for establishing a negative pressure or suction. A needle having a sharpened point and a central bore is connected to the proximal end of the housing body. An aperture is formed in a sidewall of the needle near the sharpened end. An inner hollow reciprocal cutter is fitted in the central bore of the needle and has a cutting edge adapted for travel across the aperture. A first manually actuatable lever is pivotably mounted to the housing body and coupled in driving relationship with the reciprocal cutter. A valve assembly is operatively positioned between the needle and the variable volume cavity and arranged to open to apply suction to the needle central bore as the reciprocal cutter travels across the aperture so as to withdraw vitreous material falling into the hollow cutter. A pressurized source of fluid is coupled by a conduit through the central bore of the needle and cutter and selectively actuated to replace the removed vitreous material with other material such as an antibiotic.
Owner:INSIGHT INSTR
Fibrin material and method for producing and using the same
This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion barrier. In this invention, thrombin is no longer the variable which governs the tightness and the porosity of the fibrin material obtained, but still controls the clotting time. The mechanical behavior, high-water capacity, and releasable retention properties for therapeutic agents of this fibrin structure causes the fibrin material to be ideally suited for use as a drug delivery device, capable of delivering proteins, hormones, enzymes, antibiotics, antineoplastic agents and even cells for local and systemic treatment of human and non-human patients.
Owner:BAXTER INT INC
Probiotic bacteria and methods
InactiveUS20060067924A1Reduce colonizationAssess healthBiocideBacteria material medical ingredientsMicroorganismAntibiotic Y
Provided herein are molecular methods for assessing the state of gastrointestinal microflora of an animal, especially a species of poultry, and methods for identifying probiotic bacteria by comparing certain bacteria present in animals fed a diet not containing antibiotics but absent or present in significantly lower numbers in animals fed a diet containing antibiotics.
Owner:UNIV OF GEORGIA RES FOUND INC
Infusion apparatus with modulated flow control
InactiveUS20050033232A1Easy to useEasy constructionFlexible member pumpsMedical devicesStored energyConstant force
A compact fluid dispenser for use in controllably dispensing fluid medicaments, such as antibiotics, oncolytics, hormones, steroids, blood clotting agents, analgesics, and like medicinal agents from prefilled containers at a uniform rate. The dispenser uniquely includes a stored energy source that is provided in the form of a substantially constant-force, compressible-expandable wave spring that provides the force necessary to continuously and uniformly expel fluid from the device reservoir. The device further includes a fluid flow control assembly that precisely controls the flow of medicament solution to the patient. Additionally, the device includes a novel modulating assembly for controllably modulating the force exerted by the wave spring tending to expel the fluid from the device reservoir.
Owner:BIOQUIDDITY
Synthesis of tetracyclines and analogues thereof
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Methods, devices and formulations for targeted endobronchial therapy
ActiveUS20050211245A1Mortality rate is decreasedReduce morbidityAntibacterial agentsTracheal tubesTracheobronchitisRegimen
The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is delivered into the ventilator circuit. In one embodiment the result is achieved mechanically. In another embodiment, the result is achieved by aerosol formulation. In another aspect, the invention assures the result when aerosol is delivered directly to the airways distal of the ventilator circuit. The treatment means eliminates the dosage variability that ventilator systems engender when aerosols are introduced via the ventilator circuit. The treatment means also concentrates the therapeutic agent specifically at affected sites in the lung such that therapeutic levels of administrated drug are achieved without significant systemic exposure of the patient to the drug. The invention further provides a dose control device to govern this specialized regimen.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Beta-lactamase inhibitors
Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.
Owner:MERCK SHARP & DOHME LLC
Injectable biodegradable polymer compositions for soft tissue repair and augmentation
InactiveUS20100260703A1Pharmaceutical delivery mechanismUrinary disorderInjectable polymersActive agent
Methods for soft tissue repair and / or augmentation using injectable, biodegradable polymers are described herein. In one embodiment, the polymer compositions are liquid or pastes at room temperature. In a preferred embodiment, the polymer composition contains liquid or pasty hydroxy fatty acid-based copolyesters, polyester-anhydrides, or combinations thereof. The viscosity of the polymers increases upon contact with bodily fluid to form a solid or semisolid implant suitable for soft tissue repair and / or augmentation. In another embodiment, the polymer composition contains particles of a polymer stereocomplex. One or more active agents may be incorporated into the polymer compositions. Suitable classes of active agents include local anesthetics, anti-inflammatory agents, antibiotics, analgesics, growth factors and agents that induce and / or enhance growth of tissue within the filled cavity or control the growth of a certain type of tissue, and combinations thereof. The polymer compositions may also contain one or more additives or excipients that modify the physical and / or mechanical properties of the polymer. The polymer compositions are typically administered by injection. The injectable polymers can be used for a variety of soft tissue repair and augmentation procedures.
Owner:POLYGENE LTD
Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms
InactiveUS6582719B2Toxic reductionLong-term efficacySuture equipmentsHeavy metal active ingredientsTriclosanChlorhexidine
The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
ActiveUS20160022592A1Improve imbalanceAntibacterial agentsBiocideAntibiotic-associated diarrhoeaClostridium difficile infections
The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.
Owner:THERABIOME
Dimethicone-containing sustained release injection formulation
InactiveUS20070053943A1Prevention and treatment of problemBiocidePharmaceutical delivery mechanismDrugAnalgesic agents
A sustained release formulation by using dimeticone as the dispersion medium, which includes active ingredient (e.g., drugs against parasites, insecticides, NSAIDs, antibiotics, sex hormone like agents or oily soluble vitamins) and dimeticone as the medium. Suitable stabilizer, antioxidant, local analgesics and material for sustained release may be added. The formulation is bio-compatible, stable and injectable.
Owner:WANG YUWAN +2
Lactobacillus helveticus microcapsule, preparation and use thereof
InactiveCN101323850AOvercoming the problem of low survival rate of freeze-dryingImprove efficiencyMilk preparationMetabolism disorderFreeze-dryingDietary supplement
The invention provides a lactobacillus helveticus microcapsule as well as the preparation and application thereof, pertaining to the embedding technology of lactobacillus helveticus and aiming at microencapsulating the lactobacillus helveticus so as to solve the problems of low embedding efficiency and embedding yield in single-layer or double-layer embedment. The technical proposal adopted by the invention is that isolated soy protein, microporous starch and sodium alginate are respectively taken as the first, the second and the third layers of wall materials for microencapsulation; the three-layer embedment is carried out to the lactobacillus helveticus for the first time, wherein, in the process of preparing bacterial suspension, an orthogonal optimization protective agent is adopted to improve the livability after freeze drying. The microcapsule of the invention has strong heat resistance and acid resistance, solves the inactivation problem caused by gastric acid, digestive enzyme and antibiotic, etc. to active bacillus, is capable of releasing when reaching large intestine, and balances intestinal flora. The reusability of fermented milk is good. The lactobacillus helveticus used by the invention enriches the variety of probiotic bacteria microcapsule and is a good dietary supplement.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Fungicide composition
ActiveCN101637157AGood synergyImprove the effect of disease preventionBiocideFungicidesThiocarbamateCarbamate
The invention provides a fungicide composition containing an active component A and an active component B, and application thereof in preventing and controlling various agricultural fungal diseases. The active component A in the composition is one of two methoxyl acrylic ester compounds; and as shown above, the active component B of the compound A1 and the compound A2 is one of the following fungicide varieties: thiocarbamate compounds or salt thereof, aliphatic compounds or salt thereof, carbamate compounds or salt thereof, oxazole compounds or salt thereof, thiazole compounds or salt thereof, amide compounds or salt thereof, organophosphorus compounds or salt thereof, imidazole compounds or salt thereof, antibiotic compounds or salt thereof, pyridine compounds or salt thereof and triazole compounds or salt thereof.
Owner:SHENYANG SINOCHEM AGROCHEMICALS R&D CO LTD
Soft tissue processing
The present invention is a process for preparing soft tissue such as tendons, ligaments, cartilage, fascia, dermis, human valves and human veins for implant in a human and removes cellular components and forms an decellular matrix having as major components collagens and elastins while sterilizing the tissue. The process comprises the following steps:(1) isolating from a suitable donor a desired soft tissue sample of the biological material;(2) processing and decellularizing the soft tissue including inspection for visual defects, trimming and soaking the tissue in a detergent depending on whether the tissue is fascia or dermis and rinsing same with sterile water;(3) sterilizing the soft tissue in a vacuum and soaking the tissue in an antibiotic composition or peracetic acid depending on whether the soft tissue is fascia or dermis and rinsing same;(4) processing the tissue by cutting the tissue to size and perforating the tissue; and(5) dipping the tissue in 70% ethanol and packaging the tissue.
Owner:MUSCULOSKELETAL TRANSPLANT FOUND INC
Beta-lactam antibiotic-containing tablet and production thereof
InactiveUS6423341B1Antibacterial agentsOrganic active ingredientsLow-substituted hydroxypropylcelluloseEngineering
This invention provides beta-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a beta-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and / or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.
Owner:ASTELLAS PHARMA INC
Identification of sortase gene
Owner:RGT UNIV OF CALIFORNIA
Antibiotic Kit and Composition and Uses Thereof
The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
Owner:FOAMIX LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com